Allergan, Inc. Form 8-K
Table of Contents

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities and Exchange Act of 1934

Date of Report (Date of earliest event reported):
October 13, 2003

ALLERGAN, INC.

(Exact name of registrant as specified in its charter)

         
Delaware
(State or Other Jurisdiction
of Incorporation)		   1-10269
(Commission File Number) 		  95-1622442
(IRS Employer
Identification Number)
         
2525 Dupont Drive
Irvine, California		       92612
(Address of principal executive offices)       (Zip Code)

(714) 246-4500

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

TABLE OF CONTENTS

Item 5. Other Events and Required FD Disclosure.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
SIGNATURES
EXHIBIT INDEX
EXHIBIT 99.1

Table of Contents

Item 5. Other Events and Required FD Disclosure.

     On October 14, 2003, Allergan, Inc., a Delaware corporation (“Allergan”), announced the execution of an Agreement and Plan of Merger, dated as of October 13, 2003 (the “Merger Agreement”), by and among Allergan, Wilson Acquisition, Inc., a California corporation and wholly-owned subsidiary of Allergan (“Merger Sub”), and Oculex Pharmaceuticals, Inc., a California corporation (“Oculex”). Pursuant to the Merger Agreement, Merger Sub will merge with and into Oculex, with Oculex surviving and becoming a wholly-owned subsidiary of Allergan.

     A copy of Allergan’s press release dated October 14, 2003 announcing the execution of the Merger Agreement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

  (c)   Exhibits
     
99.1   Allergan, Inc. Press Release dated October 14, 2003.

 

Table of Contents

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    ALLERGAN, INC.
         
         
Date: October 14, 2003   By:   /s/ Eric K. Brandt
       
    Name:   Eric K. Brandt
    Title:   Corporate Vice President and Chief
        Financial Officer

 

Table of Contents

EXHIBIT INDEX

     
Exhibit    
Number   Document Description
 
99.1   Allergan, Inc. Press Release dated October 14, 2003.